Home

TC BioPharm (Holdings) plc - Warrants (TCBPW)

0.0060
-0.0037 (-38.14%)
SummaryNewsPress ReleasesChartHistorical
Previous Close0.0097
Open0.0095
Day's Range0.0040 - 0.0095
52 Week Range0.0040 - 0.0439
Volume453,504
Market Cap-
Dividend & YieldN/A (N/A)
1 Month Average Volume52,561

News & Press Releases

Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END
Via FinancialNewsMedia · January 19, 2023
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
EQNX::TICKER_START (NASDAQ:TCBP) EQNX::TICKER_END
Via FinancialNewsMedia · January 19, 2023
TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemiabenzinga.com
TC Biopharm (NASDAQ: TCBP) (NASDAQ: TCBPW) recently announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®,
Via Benzinga · November 22, 2022